Kiora PharmaceuticalsKPRX
13F holders, Q2 2024 (June 30)2holders −22
1new positions
11sold out
$4.20avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Kiora Pharmaceuticals Inc. (KPRX) in their 13F filings, down 22 from Q1 2024. 1 opened new positions and 11 sold out. The largest holders were Rosalind Advisors, Inc. ($1.1M) and Stonepine Capital Management, LLC ($840K).
- Company
- Kiora Pharmaceuticals Inc.
- CUSIP
- 49721T309
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $840K |
| Exits | 11 | $137K |
All 13F filers, Q1 2024 → Q2 2024: 200,000 shares bought and 2,238,257 shares sold, net −2,038,257 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Rosalind Advisors, Inc. | 0.85% | Reduce -88.9% | 255,555 | $1.1M |
| Stonepine Capital Management, LLC | 0.77% | New | 200,000 | $840K |
"% of holder's portfolio" is KPRX's weight in each manager's 13F, not the share of Kiora Pharmaceuticals Inc. the manager owns.